

# Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)



CrossMark



Corrado Girmenia<sup>1,\*</sup>, Anna Maria Raiola<sup>2</sup>, Alfonso Piciocchi<sup>3</sup>, Alessandra Algarotti<sup>4</sup>, Marta Stanzani<sup>5</sup>, Laura Cudillo<sup>6</sup>, Clara Pecoraro<sup>7</sup>, Stefano Guidi<sup>8</sup>, Anna Paola Iori<sup>1</sup>, Barbara Montante<sup>9</sup>, Patrizia Chiusolo<sup>10</sup>, Edoardo Lanino<sup>11</sup>, Angelo Michele Carella<sup>12</sup>, Elisa Zucchetti<sup>13</sup>, Benedetto Bruno<sup>14</sup>, Giuseppe Irrera<sup>15</sup>, Francesca Patriarca<sup>16</sup>, Donatella Baronciani<sup>17</sup>, Maurizio Musso<sup>18</sup>, Arcangelo Prete<sup>19</sup>, Antonio Maria Risitano<sup>20</sup>, Domenico Russo<sup>21</sup>, Nicola Mordini<sup>22</sup>, Domenico Pastore<sup>23</sup>, Adriana Vacca<sup>24</sup>, Francesco Onida<sup>25</sup>, Sadia Falcioni<sup>26</sup>, Giovanni Pisapia<sup>27</sup>, Giuseppe Milone<sup>28</sup>, Daniele Vallisa<sup>29</sup>, Attilio Olivieri<sup>30</sup>, Alessandro Bonini<sup>31</sup>, Elio Castagnola<sup>11</sup>, Simona Sica<sup>10</sup>, Ignazio Majolino<sup>9</sup>, Alberto Bosi<sup>8</sup>, Alessandro Busca<sup>7</sup>, William Arcese<sup>6</sup>, Giuseppe Bandini<sup>5</sup>, Andrea Bacigalupo<sup>2</sup>, Alessandro Rambaldi<sup>4</sup>, Anna Locasciulli<sup>32</sup>

<sup>1</sup> Department of Hematology, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

<sup>2</sup> Division of Hematology II, IRCCS, San Martino University Hospital – IST, Genoa, Italy

<sup>3</sup> GIMEMA Foundation, Rome, Italy

<sup>4</sup> Division of Hematology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

<sup>5</sup> Institute of Hematology and Medical Oncology, L. e A Seragnoli, Policlinico S. Orsola Malpighi, Bologna, Italy

<sup>6</sup> Stem Cell Transplant Unit, Fondazione Policlinico Tor Vergata, Tor Vergata University, Rome, Italy

<sup>7</sup> Department of Oncology and Hematology, A.O. Citta' della Salute e della Scienza di Torino, P.O. Molinette, Turin, Italy

<sup>8</sup> Department of Hematology, Azienda Ospedaliera di Careggi, Florence, Italy

<sup>9</sup> Unit of Hematology and Stem Cell Transplant, Az. Osp. S. Camillo-Forlanini, Rome, Italy

<sup>10</sup> Institute of Hematology, Policlinic A. Gemelli, Sacred Heath Catholic University, Rome, Italy

<sup>11</sup> Division of Infectious Diseases and Bone Marrow Transplant Unit, Giannina Gaslini Institute, Genoa, Italy

<sup>12</sup> Stem Cell Transplant Center, Division of Hematology, Ospedale IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy

<sup>13</sup> Division of Hematology, A.O. Ospedale Niguarda Cà-Granda, Milan, Italy

<sup>14</sup> Chair of Hematology, Osp. S. Giovanni Battista, University of Turin, Turin, Italy

<sup>15</sup> Division of Hematology, Centro Unico Regionale TMO e Terapie Emato-Oncologiche Sovramassimali "A. Neri" Ospedale Bianchi-Melacrino-Morelli, Reggio Calabria, Italy

<sup>16</sup> Clinic of Hematology, Azienda Ospedaliera-Universitaria, Ple S. Maria della Misericordia, Udine, Italy

<sup>17</sup> Transplant Center "Wilma Deplano," Ospedale oncologico Armando Businco, Cagliari, Italy

<sup>18</sup> Unit of Onco-hematology and Stem Cell Transplant, Dip. Oncologico La Maddalena, Palermo, Italy

<sup>19</sup> Oncology, Hematology and Hematopoietic Stem Cell Transplant Program, U.O. Pediatrics-Prof. Pession, S. Orsola-Malpighi, University of Bologna, Bologna, Italy

<sup>20</sup> Hematology, Department of Medicine and Surgery, University of Naples Federico II, Naples, Italy

<sup>21</sup> Chair of Hematology, Bone Marrow Transplant Unit for Adults, University of Brescia, Azienda Spedali Civili, Brescia, Italy

<sup>22</sup> Division of Hematology, Azienda Ospedaliera S.Croce e Carle, Cuneo, Italy

<sup>23</sup> Hematology Section, Department of Emergency and Organ Transplant, University of Bari, Bari, Italy

<sup>24</sup> Hematology, Bone Marrow Transplant Center, P.O. "R. Binaghi", Cagliari, Italy

<sup>25</sup> Bone Marrow Transplant Center, Ospedale Maggiore IRCCS, Milan, Italy

<sup>26</sup> Hematology Unit, Ospedale C e G Mazzoni, Ascoli Piceno, Italy

<sup>27</sup> Division of Hematology with Bone Marrow Transplant Unit, Ospedale S.G. Moscati, Taranto, Italy

<sup>28</sup> Chair of Hematology, Ferrarotto Hospital, University of Catania, Catania, Italy

<sup>29</sup> First Medical Division of Onco-hematology, Ospedale Civile di Piacenza, Piacenza, Italy

<sup>30</sup> Hematology Unit, Ospedale S. Carlo, Potenza, Italy

<sup>31</sup> Hematology Unit, IRCCS-Azienda Arcispedale S. Maria Nuova, Reggio Emilia, Italy

<sup>32</sup> Pediatrics and Pediatric Hematology Unit, Az. Osp. S.Camillo-Forlanini, Rome, Italy

## Article history:

Received 29 December 2013

Accepted 4 March 2014

## ABSTRACT

Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858

*Financial disclosure:* See Acknowledgments on page 880.

\* Correspondence and reprint requests: Corrado Girmenia, Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerativa, Azienda Policlinico Umberto I, Sapienza University of Rome, Via Benevento 8, 00161 Roma, Italy.

E-mail address: [girmenia@bce.uniroma1.it](mailto:girmenia@bce.uniroma1.it) (C. Girmenia).

1083-8791/\$ – see front matter © 2014 American Society for Blood and Marrow Transplantation.

<http://dx.doi.org/10.1016/j.bbmt.2014.03.004>

**Key Words:**

Allogeneic HSCT  
Invasive fungal disease  
Epidemiology

consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed to identify risk factors for proven/probable IFD (PP-IFD) during the early (days 0 to 40), late (days 41 to 100), and very late (days 101 to 365) phases after allo-HSCT and to evaluate the impact of PP-IFDs on 1-year overall survival. The cumulative incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12 months post-transplantation. Multivariate analysis identified the following variables as associated with PP-IFDs: transplant from an unrelated volunteer donor or cord blood, active acute leukemia at the time of transplantation, and an IFD before transplantation in the early phase; transplant from an unrelated volunteer donor or cord blood and grade II-IV acute graft-versus-host disease (GVHD) in the late phase; and grade II-IV acute GVHD and extensive chronic GVHD in the very late phase. The risk for PP-IFD was significantly higher when acute GVHD was followed by chronic GVHD and when acute GVHD occurred in patients undergoing transplantation with grafts from other than matched related donors. The presence of PP-IFD was an independent factor in long-term survival (hazard ratio, 2.90; 95% confidence interval, 2.32 to 3.62;  $P < .0001$ ). Our findings indicate that tailored prevention strategies may be useful in subpopulations at differing levels of risk for PP-IFDs.

© 2014 American Society for Blood and Marrow Transplantation.

## INTRODUCTION

Invasive fungal diseases (IFDs), particularly invasive aspergillosis (IA), represent a leading cause of morbidity and mortality in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1–14]. Ongoing challenges are presented by the continuous evolution of the incidence, timing, and prognosis of IFDs owing to changes in transplant recipient populations and antifungal strategies. Therefore, ongoing epidemiologic investigation is advisable.

Given the poor outcomes associated with IFDs in transplant recipients, there is much interest in identifying risk factors and prognostic factors that may help guide the development of tailored prevention strategies and more aggressive diagnostic and treatment approaches [2,3,8–10,12,14,15]. Although risk factors for IFDs have been evaluated extensively in allo-HSCT recipients, there are few studies describing specific variables related to outcome [1,2,8,9].

To assess the current incidence, risk factors, and prognostic factors of IFDs in allo-HSCT patients, the Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data of patients undergoing allo-HSCT between 2008 and 2010. These data provide the basis for promoting direct efforts in risk stratification, prevention, and management of IFDs in allo-HSCT recipients.

## METHODS

The surveillance involved 30 transplantation centers in Italy for a period of 3 years from January 1, 2008, to December 31, 2010. Study start time could differ among the centers, but all consecutive transplants were enrolled. Second and third allo-HSCTs were analyzed as a separate category when appropriate.

Data collection for each case was interrupted at 12 months after transplantation, and thus the study end date was December 31, 2011. Data were entered into electronic case report forms, and all reported results are derived from the database frozen at June 30, 2012. The results of this study are reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement [16]. The study was approved by the Ethical Committee of each participating center, and informed consent was obtained from the patients.

## Data Collection

Variables analyzed included patient characteristics, diagnosis and phase of the underlying disease; previous autologous HSCT (auto-HSCT) or allo-HSCT; proven, probable, or possible IFD documented within the 180 days before transplantation; cytomegalovirus (CMV) serology of donor and recipient; stem cell donor; stem cell source; pretransplantation conditioning regimen; the use of total body irradiation; the use of in vivo T cell depletion with antithymocyte globulin (ATG) or alemtuzumab; and the transplantation activity of the center (with the median number of patients enrolled [ $n = 48$ ] used to stratify 15 centers with high transplantation activity and 15 centers with low activity). Post-transplantation data included primary and secondary antifungal prophylaxis during the engraftment phase and, in the event of graft-versus-host disease (GVHD), grade II-IV acute GVHD (aGVHD) and extensive chronic GVHD (cGVHD) diagnosed and staged according to standard criteria [17], CMV reactivation, remission

status of underlying diseases, proven and probable IFDs (PP-IFDs), survival, and causes of death. Information pertaining to PP-IFDs included timing after allo-HSCT, microbiological data, and site of infection.

## Case Definitions

Cases of PP-IFD were defined according to standard international criteria [18]. The clinical and laboratory data reported to define cases of PP-IFD were reviewed to determine the reliability of the diagnosis. Cases with IFD diagnosed before transplantation were analyzed as a separate category when appropriate. Onset of PP-IFD was defined as the day of the first positive radiologic exam, positive culture, or positive pathological test. PP-IFDs were classified as early (occurring  $\leq 40$  days after allo-HSCT), late (occurring 41 to 100 days after allo-HSCT), or very late (occurring 101 to 365 days after allo-HSCT), consistent with previous analyses [9,10]. The cutoff of 40 days for early PP-IFDs was chosen to ensure that the model reflected the engraftment period. The day 41 to day 100 interval for late PP-IFDs reflects the immediate postengraftment period, the risk of developing aGVHD, and early immunologic recovery. The cutoff of 101 to 365 days for very late PP-IFDs reflects the late or post-aGVHD period, the cGVHD period, and late immunologic recovery.

## Analyses

The 12-month cumulative incidence of PP-IFDs was calculated accounting for the competing risks of infection-free death, retransplantation, and relapse of the underlying disease. The cumulative incidence of PP-IFDs was calculated for any type and status of the underlying disease; any type of stem cell donor, stem cell source, and pretransplant conditioning; history of IFD before transplantation; type of primary antifungal prophylaxis; aGVHD and cGVHD; and CMV infection/reactivation. Cumulative incidence was assessed using the *cmprsk* package in R version 2.15 (R Project for Statistical Computing, Vienna, Austria). The associations among early, late and very late PP-IFDs and the foregoing risk factors were evaluated by landmark analysis. All factors were evaluated in multivariate models to control for potential confounders. Crude mortality rates at 100 days after PP-IFD and at 12 months post-transplantation were calculated. Death was attributed to a PP-IFD in patients who failed to respond to therapy (ie, who had stable disease or disease progression) and in patients who demonstrated a partial response to therapy who died as the result of an acute event involving any of the sites of infection and in the absence of any other causes considered to have primarily contributed to death.

Survival analyses were performed on the basis of the foregoing variables. The probability of 1-year survival from allo-HSCT was calculated using the Kaplan-Meier estimate, and the log-rank test was applied for univariate analyses. A 2-sided  $P$  value  $< .05$  was considered to indicate statistical significance. Multivariate analyses were performed with the Cox proportional hazards regression model. The variables PP-IFD, aGVHD, cGVHD, and CMV infection/reactivation in the model were considered time-dependent covariates, with their effect evaluated only in the period after their onset. All significant variables in univariate analysis were included in multivariate analysis; final models were also evaluated with backward and stepwise functions. In all, 95% confidence intervals (CIs) are reported for the main summary statistics, and all statistical comparisons were based on 2-tailed tests. Statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC). All comparisons were 2-sided, with a nominal significance level of 5%.

## RESULTS

### Patient Characteristics

The 1858 allo-HSCTs analyzed in the study included 1771 first allo-HSCTs, 85 second allo-HSCTs, and 2 third allo-HSCTs.

Overall, 425 allo-HSCTs (22.9%) were preceded by an auto-HSCT. The median number of transplants per center was 48.5 (range, 9 to 228). Demographic data and patient characteristics at the time of allo-HSCT are summarized in Table 1.

### Antifungal Prophylaxis

During the engraftment period, 92 patients who had experienced an IFD before transplantation (4.9%) received

secondary antifungal prophylaxis, 1401 patients (75.4%) received primary antifungal prophylaxis with fluconazole only, 263 (14.1%) received primary antifungal prophylaxis with a mold-active drug, and 102 (5.5%) received no antifungal prophylaxis. Among the 641 patients who experienced grade II–IV aGVHD and/or extensive cGVHD and did not receive antifungal therapy owing to a previous IFD, only 133 (20.7%) received mold-active primary antifungal prophylaxis. Considering that mold-active primary antifungal prophylaxis in patients with GVHD was given in a minority of patients and consisted of various drugs (liposomal amphotericin B, voriconazole, itraconazole, posaconazole, and caspofungin) administered alone or sequentially with heterogeneous start-and-stop timing after transplantation and frequently with intermittent administration, the variable “primary antifungal prophylaxis” administered after engraftment in patients with GVHD was not included in our risk analyses. In contrast, primary antifungal prophylaxis administered during the engraftment period was included in the variables considered for the PP-IFD risk analysis.

### Incidence of PP-IFDs

Overall, in 164 of 1858 transplants (8.8%), a new PP-IFD or reactivation of a previous IFD was documented before the presence of any competing risk. IA was the most common infection (133 cases; 81.1%), followed by invasive candidiasis (18 cases, 11.0%), zygomycosis (6 cases, 3.7%), fusariosis (3 cases, 1.8%), and infections by other fungi (*Scedosporium* sp, *Scopulariopsis* sp, *Cryptococcus neoformans*, and *Geotrichum capitatum*, 1 case each).


The cumulative incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12 months from transplantation (Figure 1). One competing risk was present in 769 cases (41.4%). The rate of PP-IFDs at the transplantation

**Table 1**  
Characteristics of Patients at Allo-HSCT (n = 1858)

Characteristic	Value
Age, yr, median (range)	43 (1–72)
Age ≤18 yr, n (%)	205 (11)
Male sex, n (%)	1072 (57.7)
Underlying disease, n (%)	
Acute myelogenous leukemia	685 (36.9)
Acute lymphoblastic leukemia	325 (17.5)
Biphenotypic acute leukemia	7 (0.04)
Myelodysplastic syndromes	119 (6.4)
Chronic myeloproliferative diseases	142 (7.6)
Non-Hodgkin lymphoma	192 (10.3)
Hodgkin lymphoma	90 (4.8)
Chronic lymphocytic leukemia	48 (2.6)
Aplastic anemia	68 (3.7)
Multiple myeloma and plasmacellular leukemia	122 (6.6)
Hemoglobinopathies	19 (1.0)
Solid tumors	15 (0.8)
Other diseases	26 (1.4)
Phase of underlying disease at allo-HSCT, n (%)	
Malignancies in complete remission	977 (52.6)
Malignancies not in complete remission	768 (41.3)
remission/active*	
Nonmalignant stable/ chronic diseases	113 (6.1)
Previous HSCT, n (%)	
Auto-HSCT alone	418 (22.5)
Allo-HSCT (in 7 cases preceded by auto-HSCT)	87 (4.7)
Donor type, n (%)	
HLA-matched related	849 (45.7)
HLA-mismatched related†	110 (5.9)
Unrelated volunteer	720 (38.7)
Unrelated cord blood	179 (9.6)
Stem cell source, n (%)	
Bone marrow	581 (31.3)
Peripheral blood	1098 (59.1)
Cord blood	179 (9.6)
Pretransplantation conditioning, n (%)	
Myeloablative	1179 (63.4)
Reduced-intensity	368 (19.8)
Nonmyeloablative	679 (36.5)
CMV serostatus (n = 1803), n (%)	
Recipient negative/donor negative	188 (10.4)
Recipient negative/donor positive	137 (7.6)
Recipient positive/donor positive	969 (53.7)
Recipient positive/donor negative	509 (28.2)
IFD in the 180 d before allo-HSCT, n (%)	
Proven/probable IA	51 (54.8)
Proven candidosis	5 (5.4)
Proven/probable mucormycosis	3 (3.2)
Other proven/probable IFD	2 (2.1)
Possible IFD	32 (34.4)
Phase of previous IFD at allo-HSCT, n (%)	
Infection in complete remission	44 (47.3)
Infection not in complete remission	49 (52.7)
Patients enrolled in the centers with the greatest	1381 (74.3)
HSCT activity, n (%)	
Patients enrolled in the centers with the least	477 (25.7)
HSCT activity, n (%)	

\* Among 1017 patients with acute leukemia, 231 (26.7%) were not in CR at the time of allo-HSCT.

† The 110 transplants from HLA-mismatched related donors included 72 haploidentical transplants.



**Figure 1.** Cumulative incidence curve for IFDs among allo-HSCT recipients in the GITMO epidemiologic survey.

centers ranged from 0% to 23.1% (Figure 2). The 12-month cumulative incidence of PP-IFD was 9.9% in the 15 centers with the highest transplantation activity and 5.7% in the 15 centers with the lowest activity ( $P = .004$ ). The cumulative incidence of PP-IFDs according to demographics, underlying disease, and transplantation variables is presented in Table 2.

#### Risk Factors for PP-IFD in the Early, Late, and Very Late Phases after Allo-HSCT

The 164 cases of PP-IFD included 94 (57.3%) early, 39 (23.8%) late, and 31 (18.9%) very late cases. The early phase had the highest rate of IFD irrespective of fungal pathogen (Figure 3). In a landmark analysis, the cumulative incidence of PP-IFDs was 5.1% in the early phase, 1.9% in the late phase, and 2.9% in the very late phase. Risk factors for PP-IFD during each phase after allo-HSCT are shown in Table 3.

On multivariate analysis, variables associated with early PP-IFDs were receipt of a transplant from an unrelated volunteer donor (UD) or cord blood (CB), active acute leukemia at the time of transplantation, and an IFD before transplantation. Late PP-IFDs were predicted by receipt of a UD or CB transplant and grade II-IV aGVHD; very late PP-IFDs, by grade II-IV aGVHD and extensive cGVHD. The risk of early PP-IFD was greater ( $P = .06$ ) in centers with higher transplantation activity compared with centers with lower activity. Table 4 presents the cumulative incidence estimates of PP-IFDs according to the variables identified as independent risk factors during the various phases after allo-HSCT.

#### Risk of PP-IFD in Patients with aGVHD or cGVHD

After excluding 20 patients who developed a PP-IFD before the occurrence of GVHD, 641 patients who experienced grade II-IV aGVHD and/or extensive cGVHD were included in this analysis. A PP-IFD was documented in 28 of 388 patients (7.2%) with aGVHD not followed by cGVHD, in 25 of 129 patients (19.4%) with aGVHD followed by cGVHD, and in 4 of 124 patients (3.2%) with cGVHD not preceded by aGVHD (ie, “de novo” cGVHD). The median interval from the onset of GVHD to detection of IFD was 38 days for patients with aGVHD not followed by cGVHD, 80 days for patients

with aGVHD followed by cGVHD, and 25.5 days for patients with cGVHD not preceded by aGVHD (Figure 4).

The cumulative incidence of PP-IFD, starting from GVHD onset, is shown in Figure 5 according to GVHD group and donor type. In patients with aGVHD not followed by cGVHD, the cumulative incidence of PP-IFD was 2.3% in recipients of allo-HSCT from a matched related donor (MRD) and 10% in recipients of allo-HSCT from an alternative donor (mismatched related donor [MMRD], UD, or CB) ( $P = .0039$ ). In allo-HSCT recipients with aGVHD followed by cGVHD, the cumulative incidence of PP-IFD was 10% in recipients of an MRD graft and 25.3% in recipients of a graft from an alternative donor ( $P = .06$ ). In patients with de novo cGVHD, the cumulative incidence of PP-IFD was 3% for the former group 3.5% for latter ( $P = .90$ ). The cumulative incidence of PP-IFDs at 6 months after onset of GVHD was 7.1% in 334 patients with a grade II aGVHD and 12.3% in 178 patients with grade III-IV aGVHD ( $P = .049$ ).

#### Survival

The mortality rate at 100 days from the diagnosis of PP-IFD was 46.3% (76 of 164 patients). In patients with IA, invasive candidiasis, and non-*Aspergillus*–non-*Candida* infections, it accounted for 48.5%, 39%, and 75%, respectively. Among the 76 patients who died within 100 days from the diagnosis of a PP-IFD, the infection was considered the primary cause of death in 34 (44.7%), with an attributable mortality rate of 20.7%. The probability of survival to 6 months after diagnosis of PP-IFD was roughly 55% in patients in the early, late and very late phases after receipt of allo-HSCT (Figure 6).

The overall survival of the entire population at 1 year after allo-HSCT was 64.4% (95% CI, 62.2% to 66.6%). Multivariate analysis identified older age, active acute leukemia at transplantation, IFD in the 180 days before transplantation, receipt of a CB transplant, receipt of a UD transplant, aGVHD, and PP-IFD (hazard ratio [HR], 2.90; 95% CI, 2.32 to 3.62;  $P < .0001$ ) as independent survival factors (Table 5).

#### DISCUSSION

Few large, prospective surveillance studies on IFDs in allo-HSCT recipients have been published to date [12,13]. A study





Figure 2. Distribution of total allo-HSCTs performed and the number and rate of IFDs in the 30 transplantation centers.



**Table 2**  
Cumulative Incidence of IFD at 1 Year According to Demographic, Underlying Disease, and Transplantation Variables

Variable	Estimated Cumulative Incidence, %	95% CI	P Value
Sex			
Male	8.58	7.00–10.36	.66
Female	9.16	7.27–11.31	
Underlying disease			
Acute leukemia	8.95	7.29–10.80	.82
Other	8.68	6.90–10.71	
Phase of underlying disease at allo-HSCT			
CR	7.88	7.42–9.18	.02
No CR/chronic	10.37	8.47–12.49	
Previous HSCT			
No	9.02	7.57–10.62	.44
Yes, autologous alone	7.66	5.36–10.47	
Yes, allogeneic	11.49	5.86–19.22	
IFD in the 180 d before allo-HSCT			
No	8.27	7.05–9.62	.0001
Yes	19.35	12.03–27.98	
CMV serostatus			
Donor positive, recipient positive	7.33	5.80–9.08	.001
Donor positive, recipient negative	7.30	3.72–12.47	
Donor negative, recipient positive	12.97	10.22–16.05	
Donor negative, recipient negative	5.32	2.72–9.19	
Stem cell source			
Bone marrow	9.12	6.96–11.64	<.0001
Peripheral blood	7.29	5.85–8.92	
Cord blood	17.32	12.17–23.23	
Donor type			
HLA-matched related	4.60	3.34–6.17	<.0001
HLA-mismatched related	8.18	4.00–14.28	
Unrelated volunteer	11.77	9.55–14.25	
Unrelated cord blood	17.32	12.17–23.23	
Conditioning regimen			
Myeloablative	8.23	6.75–9.89	.24
Nonmyeloablative/reduced-intensity	9.87	7.77–12.25	
In vivo T cell depletion			
No	5.32	3.93–7.00	<.0001
Yes	11.64	9.77–13.68	
Total body irradiation			
No	7.86	6.48–9.41	.03
Yes	11.07	8.64–13.84	
Mold-active primary antifungal prophylaxis during engraftment			
Yes	4.58	4.14–5.48	.02
No	8.95	7.90–10.15	
Center HSCT activity			
Highest	9.92	8.41–11.57	.004
Lowest	5.66	3.83–7.99	

from the sentinel surveillance system of the Transplant-Associated Infections Surveillance Network (TRANSNET) evaluated the incidence and burden of IFDs in 6666 allogeneic HSCTs performed between March 2001 and March 2006 in 23 transplantation centers (representing approximately 20% of HSCT recipients in the United States during the study period) with the aim of estimating the cumulative incidence of PP-IFDs and collecting clinical, diagnostic, and outcome information for each reported infection [12]. A study by the Prospective Antifungal Therapy (PATH) Alliance registry collected data and monitored trends in epidemiologic characteristics, diagnosis, treatment, and outcomes of 234 allo-HSCT recipients with PP-IFD observed in 23 centers in the United States and Canada between July 2004 and September 2007 [13].



**Figure 3.** Timing of IFD. Early IFD refers to infection diagnosed on days 0–40 after allo-HSCT; late IFD, to infection diagnosed on days 41–100; and very late IFD, to infection diagnosed after day 100.

The present GITMO survey, which includes approximately 40% of allo-HSCTs performed in Italy during the years 2008 to 2010, was a prospective study designed to critically assess not only the incidence, but also the risk factors for and prognostic role of PP-IFDs at 1 year from allo-HSCT. A valuable characteristic of this study is the availability of complete denominator data collected prospectively for consecutive allo-HSCT recipients at each center.

The overall 12-month cumulative incidence of PP-IFDs was 8.8%. Of these PP-IFDs, 81% were caused by IA and 11% were caused by *Candida* species, with other infections relatively uncommon. The incidence of PP-IFDs by allo-HSCT graft source was 4.6% for MRD, 8.2% for MMRD, 11.8% for UD, and 17.3% for CB. These results are comparable in some respects to those reported in the TRANSNET survey, with 12-month cumulative incidences of 5.8% for MRD, 8.1% for MMRD, and 7.7% for UD (with specific data for the few CB transplants not reported) [12]. The incidence of PP-IFDs among centers ranged from 0% to 23%, with the highest incidences in the larger centers. A potential center effect may represent a limit of our survey and of any multicenter trial. To evaluate the potential role of the different clinical care habits, we stratified the centers according to transplantation activity, which may reflect the different types of transplants and care capabilities. Multivariate analysis did not identify transplantation activity as an independent risk factor, although it was borderline significant in the early phase after allo-HSCT. The site-specific variation in the incidence of PP-IFDs may reflect differences in patient populations, transplantation programs, and diagnostic accuracy, particularly for mold infections.

The timing of PP-IFDs in our study was rather unexpected: indeed, early infections represented 57.3% of all infections documented during the first year after allo-HSCT. This result contrasts with previous studies in which the vast majority of cases were documented after the engraftment period [8,12]. Several factors may explain the high incidence of PP-IFDs during the early transplantation phase in our series. Transplant with a UD or CB graft, active acute leukemia at the time of transplantation, and an IFD before transplantation were found to be independent factors for the development of an early PP-IFD. One or more of these conditions were present in more than one-half of the patients in our study, in line with the increasing use of transplants from alternative donors and a trend toward less-restrictive eligibility criteria worldwide. The high risk for early IFDs in patients who receive a transplant from an alternative donor, particularly CB, or in those with a history of infection before

**Table 3**  
Risk Factors for IFD in 1858 Allo-HSCTs during the Early (Days 1–40), Late (Days 41–100) and Very Late (Days 101–365) Phases

Variable	Early IFD (n = 94)				Late IFD (n = 31)				Very Late IFD (n = 39)			
	Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate	
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Age	1.0 (0.99–1.01)	.81			0.97 (0.95–0.99)	.02			0.99 (0.97–1.01)	.57		
Sex, female versus male	1.06 (0.70–1.59)	.8			1.88 (0.92–3.83)	.08			0.70 (0.36–1.35)	.29		
Underlying disease, acute leukemia versus other	1.18 (0.78–1.77)	.43			0.59 (0.29–1.2)	.15			1.18 (0.63–2.24)	.6		
Phase of any underlying disease at allo-HSCT, CR versus no CR	0.51 (0.34–0.78)	.0017			0.76 (0.38–1.53)	.44			1.01 (0.53–1.91)	.98		
Phase of the underlying disease at allo-HSCT												
Acute leukemia in CR versus no CR	0.27 (0.16–0.46)	<.0001	0.29 (0.17–0.49)	<.0001	1.23 (0.27–5.56)	.78			1.55 (0.37–6.53)	.55		
Other in CR versus acute leukemia no CR	0.30 (0.13–0.68)	.004	0.39 (0.17–0.91)	.03	1.96 (0.36–10.68)	.44			0.64 (0.09–4.52)	.65		
Other no CR versus acute leukemia no CR	0.38 (0.23–0.63)	.0002	0.45 (0.27–0.77)	.003	2.04 (0.46–8.97)	.35			1.44 (0.33–6.29)	.63		
Previous allo-HSCT, no versus yes	0.51 (0.25–1.06)	.73			1.34 (0.18–9.83)	.77			1.62 (0.23–11.6)	.63		
IFD in the 180 d before allo-HSCT, no versus yes	0.26 (0.15–0.45)	<.0001	0.27 (0.15–0.48)	<.0001	0.39 (0.12–1.27)	.12			Not converged			
CMV serostatus												
Donor+/recipient– versus donor+/recipient+	1.31 (0.58–2.93)	.51			1.30 (0.38–4.44)	.68			Not converged			
Donor–/recipient+ versus donor+/recipient+	1.98 (1.26–3.09)	.003			1.25 (0.57–2.75)	.58						
Donor–/recipient– versus donor+/recipient+	0.67 (0.27–1.69)	.4			0.31 (0.04–2.36)	.26						
Stem cell source												
Peripheral blood versus bone marrow	1.13 (0.69–1.86)	.6			0.62 (0.29–1.34)	.23			0.52 (0.27–1.01)	.053		
Cord blood versus bone marrow	3.23 (1.81–5.77)	<.0001			1.67 (0.59–4.71)	.34			0.94 (0.32–2.78)	.91		
Donor type												
Mismatched related versus matched related	2.37 (0.94–5.92)	.07	1.90 (0.75–4.81)	.18	1.79 (0.21–15.1)	.59	1.41 (0.16–12.14)	.75	1.31 (0.30–5.73)	.72		
Unrelated volunteer versus matched related	2.76 (1.64–4.66)	.0002	2.86 (1.68–4.84)	.0001	5.05 (1.89–13.5)	.001	3.73 (1.38–10.02)	.009	1.80 (0.90–3.59)	.09		
Unrelated cord blood versus matched related	5.45 (2.98–9.95)	<.0001	4.60 (2.43–8.69)	<.0001	6.05 (1.75–20.9)	.004	4.64 (1.32–16.31)	.017	1.83 (0.60–5.54)	.29		
Myeloablative conditioning, yes versus no	0.89 (0.59–1.34)	.56			0.77 (0.38–1.56)	.47			0.69 (0.37–1.3)	.26		
T cell depletion in conditioning, yes versus no	2.53 (1.58–4.04)	.0001			1.8 (0.85–3.83)	.12			2.26 (1.13–4.53)	.02		
Total body irradiation in conditioning, yes versus no	1.51 (1.0–2.29)	.05			1.54 (0.75–3.17)	.24			1.18 (0.61–2.29)	.63		
Mold-active primary antifungal prophylaxis during engraftment, yes versus no	0.46 (0.20–1.06)	.06			0.69 (0.21–2.28)	.54			0.53 (0.16–1.71)	.29		
Grade II–IV aGVHD	0.83 (0.25–2.74)	.76			6.81 (3.14–14.8)	<.0001	5.93 (2.71–12.98)	<.0001	5.06 (2.60–9.85)	<.0001	3.80 (1.90–7.59)	.0002
Extensive cGVHD	NA	NA			NA	NA			5.99 (3.10–11.57)	<.0001	3.98 (2.02–7.82)	<.0001
CMV reactivation/infection	1.07 (0.33–3.54)	.91			1.86 (0.92–3.79)	.09			1.85 (0.98–3.50)	.06		
Center HSCT activity, highest versus lowest	2.39 (1.31–4.39)	.005	1.85 (0.98–3.48)	.06	1.88 (0.72–4.91)	.19			1.08 (0.53–2.20)	.84		

NA indicates not applicable.

**Table 4**

Cumulative Incidence of IFD According to the Variables Identified as Independent Risk Factors during the Early, Late, and Very Late Phases after Allo-HSCT

Variable	Early IFD		Late IFD		Very Late IFD	
	Estimate, %	95% CI	Estimate, %	95% CI	Estimate, %	95% CI
Underlying disease and disease phase at allo-HSCT						
Acute leukemia in CR	3.43	3.43–3.44	NS	NS	NS	NS
Acute leukemia not in CR	12.12	12.03–12.21				
Other disease in CR	3.78	3.74–3.82				
Other disease not in CR	4.88	4.86–4.89				
Previous IFD in the 180 d before allo-HSCT						
No	4.48	4.47–4.48	NS	NS	NS	NS
Yes	16.13	15.84–16.42				
Donor type						
Matched related	2.47	2.46–2.48	0.633	0.631–0.634	NS	NS
Mismatched related	5.45	5.36–5.54	1.14	1.11–1.16		
Unrelated volunteer	6.37	6.35–6.39	3.17	3.16–3.18		
Unrelated cord blood	11.86	11.75–11.98	3.82	3.76–3.87		
aGVHD grade						
0–I	NS	NS	0.793	0.791–0.794	1.348	1.346–1.351
II–IV			4.36	4.34–4.37	6.52	6.49–6.55
cGVHD						
None or limited	NA	NA	NA	NA	1.704	1.701–1.707
Extensive					8.06	8.0–8.12

NS indicates not significant; NA, not applicable.


transplantation is well known [5–7,10,19]; however, the high rate of early PP-IFDs in patients with active acute leukemia at the time of transplantation is an original finding. The severe immunologic impairment associated with active disease, multiple intensive chemotherapy treatments, and late engraftment frequently seen in these patients may justify the high early post-transplantation risk of PP-IFD [20–22].


GVHD represents a known risk factor for IFD, and mold-active primary antifungal prophylaxis is recommended in patients with GVHD while receiving initiation of immunosuppressive therapy [2,23,24]. Our study confirms that aGVHD and cGVHD are independent risk factors for the development of late and very late PP-IFDs. The subanalysis of patient populations with different types and severity of GVHD and different donors revealed a significantly different risk profile, however. The cumulative incidence of PP-IFDs was high in patients with aGVHD developing after transplantation from an alternative donor, and was even higher when aGVHD was followed by cGVHD regardless of donor type, up to 25% in recipients of an alternative donor graft. Of interest, the cumulative incidence of PP-IFDs was relatively

low (<4%) in patients with de novo cGVHD regardless of donor type. As expected, the risk for PP-IFD was significantly higher in patients with grade III–IV aGVHD compared with those with grade II aGVHD [2].

In this study, we were not able to evaluate the impact of mold-active primary antifungal prophylaxis on the epidemiology of post-transplantation PP-IFDs either during the engraftment period or in the event of GVHD, likely related to the wide variability in prophylaxis according to clinical indication, type of antifungal drug, and timing and duration of administration. The real life data from our study demonstrate the difficulty of applying the guidelines for antifungal prophylaxis in the various clinical settings of allo-HSCT, and suggest the need for risk- and time-adapted indications [14,24].

Reported mortality rates in allo-HSCT recipients with IFD have been as high as 80% [1,13,25]; however, more recent data seem to show improving outcomes, particularly for IA, possibly related to the extensive use of voriconazole [8,15,26]. In the PATH Alliance study, the overall mortality rate at 12 weeks after documented IA was 35.5% [13],


**Figure 4.** Distribution of time to IFD stratified by type of GVHD.



**Figure 5.** Cumulative incidence of IFD from GVHD onset by type of GVHD (A) and by type of donor (B).

compared with the 48.5% rate in our study. Of interest, mortality attributed to PP-IFD was 20.7%, confirming the improvement in therapeutic approaches to these infections with favorable impacts on short-term outcome.

Whereas in previous studies, outcomes of IFDs were usually evaluated at 3 months after transplantation, we



**Figure 6.** Probability of 6-month survival after diagnosis of early PP-IFD, late PP-IFD, and very late PP-IFD.

chose to evaluate outcomes at 1 year. In our study, in addition to the well-known factors predicting poor outcome, including older age, active acute leukemia at transplantation, IFD before transplantation, alternative donor graft, and aGVHD, PP-IFDs represent an independent prognostic factor for survival. This finding suggests that although PP-IFDs may be cured or controlled in most cases, they are of poor prognostic significance, likely because of the underlying condition that favored the development of the infection, and also because of the possible interference of IFD with the management of other post-transplantation complications, such as GVHD, viral infection, and hematologic relapse.

**Table 5**  
Probability of Overall Survival at 1 Year from Allo-HSCT

Variable	Univariate Analysis		Multivariate Analysis	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Male versus female	0.99 (0.85–1.16)	.9		
Age (increased by 10)	1.12 (1.06–1.17)	<.0001	1.14 (1.10–1.19)	<.0001
Underlying disease, acute leukemia versus other	1.09 (0.93–1.27)	.28		
Phase of any underlying disease at allo-HSCT, CR versus no CR	0.56 (0.48–0.66)	<.0001		
Phase of the underlying disease at allo-HSCT				
Acute leukemia in CR versus acute leukemia no CR	0.29 (0.23–0.35)	<.0001	0.36 (0.29–0.45)	<.0001
Other in CR versus acute leukemia no CR	0.31 (0.23–0.42)	<.0001	0.41 (0.30–0.56)	<.0001
Other no CR versus acute leukemia no CR	0.39 (0.32–0.48)	<.0001	0.49 (0.40–0.61)	<.0001
Previous allo-HSCT, no versus yes	0.59 (0.43–0.80)	.0006		
Previous IFD in the 180 d before allo-HSCT, no versus yes	0.49 (0.37–0.65)	<.0001	0.57 (0.43–0.76)	0.0001
CMV serostatus				
Donor+/recipient– versus donor+/recipient+	0.99 (0.73–1.35)	.94		
Donor–/recipient+ versus donor+/recipient+	1.20 (1.01–1.43)	.04		
Donor–/recipient– versus donor+/recipient+	0.85 (0.64–1.12)	.27		
Stem cell source				
Peripheral blood versus bone marrow	1.11 (0.93–1.32)	.24		
Cord blood versus bone marrow	1.77 (1.37–2.29)	<.0001		
Donor type				
Mismatched related versus matched related	2.04 (1.52–2.74)	<.0001	1.81 (1.34–2.44)	<.0001
Unrelated volunteer versus matched related	1.40 (1.18–1.66)	.0001	1.34 (1.13–1.60)	<.0001
Unrelated cord blood versus matched related	2.02 (1.58–2.59)	<.0001	1.81 (1.40–2.35)	<.0001
Myeloablative conditioning, yes versus no	0.87 (0.75–1.02)	.09		
T cell depletion in conditioning, yes versus no	1.25 (1.07–1.46)	.004		
Total body irradiation in conditioning, yes versus no	0.98 (0.83–1.16)	.79		
Center HSCT activity, highest versus lowest	1.08 (0.91–1.29)	.39		
Grade II–IV aGVHD	1.58 (1.34–1.86)	<.0001	1.46 (1.23–1.72)	<.0001
Extensive cGVHD	1.69 (1.31–2.19)	<.0001		
CMV reactivation/infection	1.46 (1.24–1.72)	<.0001		
PP-IFD after allo-HSCT, yes versus no	3.89 (3.14–4.79)	<.0001	2.90 (2.32–3.62)	<.0001



In conclusion, our study has identified important risk factors for PP-IFD during the preengraftment and post-engraftment phases in a real life allo-HSCT scenario. The demonstration of an independent impact of these complications on transplantation outcomes suggests the need for changes in supportive care strategies to decrease the burden of IFD in allo-HSCT recipients. Of relevance, our experience shows an absence of consensus in the practice of antifungal prophylaxis in the allo-HSCT community, likely related to the lack of specific epidemiologic information. Our present findings may be useful in identifying the subpopulations of allograft recipients who might benefit from targeted prevention strategies.

## ACKNOWLEDGMENTS

The authors thank Roberto Ricci for his valuable assistance with data management.

**Conflict of interest statement:** There are no conflicts of interest to report.

**Financial disclosure:** The authors have nothing to disclose.

## REFERENCES

- Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin Infect Dis*. 2002;34:909–917.
- Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood*. 2002;100:4358–4366.
- Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. *Blood*. 2003;102:827–833.
- Saaavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. *Bone Marrow Transplant*. 2002;30:937–943.
- Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late post-transplant infections in adult and pediatric patients, 1996–2005. *Medicine (Baltimore)*. 2007;86:324–333.
- Miyakoshi S, Kusumi E, Matsumura T, et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. *Biol Blood Marrow Transplant*. 2007;13:771–777.
- Parody R, Martino R, Rovira M, et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. *Biol Blood Marrow Transplant*. 2006;12:734–748.
- Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. *Clin Infect Dis*. 2007;44:531–540.
- Garcia-Vidal C, Upton A, Kirby KA, Marr A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. *Clin Infect Dis*. 2008;47:1041–1050.
- Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. *Bone Marrow Transplant*. 2009;44:361–367.
- Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne). *Clin Infect Dis*. 2007;45:1161–1170.
- Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis*. 2010;50:1091–1100.
- Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of the Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. *Clin Infect Dis*. 2009;48:265–273.
- Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Clin Infect Dis*. 2009;49:1226–1236.
- Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. *Clin Infect Dis*. 2001;32:358–366.
- von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61:344–349.
- Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. *Am J Med*. 1980;69:204–217.
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis*. 2008;46:1813–1821.
- Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2006;108:2928–2936.
- Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. *Leukemia*. 2011;25:808–813.
- Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. *J Clin Oncol*. 2010;28:3730–3738.
- Todisco E, Ciceri F, Oldani E, et al. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after amyeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). *Leukemia*. 2013;27:2086–2091.
- Wingard JR. Fungal infections after bone marrow transplant. *Biol Blood Marrow Transplant*. 1999;5:55–68.
- Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. *Bone Marrow Transplant*. 2011;46:709–718.
- Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. *Clin Infect Dis*. 2006;42:955–963.
- Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. *Clin Infect Dis*. 2010;50:1559–1567.